Blood Pressure and Your Genetics
Written by Scott Peeples, BS Biomedical Sciences · ExomeDNA Founder
Research base: Moderate.
Mean arterial pressure adjusted for body mass index isolates genetic effects on blood pressure that are independent of obesity-mediated pathways. Pozarickij et al. (2024) identified 85 associated genes for BMI-adjusted MAP. Top-ranked signals include FGF5, SWAP70, CACNA1D, TBC1D12, and APOA1. The presence of APOA1 — encoding the principal HDL cholesterol protein — and ANO1 — encoding a vascular smooth muscle calcium-activated chloride channel — gives this BMI-adjusted MAP analysis distinctive lipid-endothelial and ion channel angles not prominent in unadjusted MAP analyses.
What is mean arterial pressure?
Mean arterial pressure is the time-averaged force exerted on arterial walls throughout the cardiac cycle, calculated approximately as diastolic blood pressure plus one-third of pulse pressure. It is the primary hemodynamic driver of tissue perfusion. Persistent MAP elevation above normal ranges is associated with graded increases in cardiovascular and renal burden.
BMI adjustment statistically removes the contribution of body weight to blood pressure, isolating genetic effects that operate through direct vascular mechanisms rather than adiposity as an intermediary. Variants identified in a BMI-adjusted MAP GWAS reflect constitutional blood pressure biology — the inherited setpoint that would persist even without weight gain.
The genetics behind mean arterial pressure
Pozarickij et al. (2024) identified 85 associated genes for BMI-adjusted MAP. Top-ranked signals:
FGF5 (rank 1 by gene prioritization) encodes fibroblast growth factor 5 — the most consistently replicated blood pressure locus across global populations and phenotype definitions. Its rank-1 position in the BMI-adjusted analysis confirms that FGF5's vascular smooth muscle signaling effect operates independently of body weight.
SWAP70 (rank 2) encodes a Rho GTPase exchange factor involved in actin cytoskeletal remodeling. SWAP70 co-localizes with FGF5 on chromosome 4 across multiple blood pressure GWAS. Both signals are preserved after BMI adjustment, confirming their independence from adiposity-mediated pathways.
CACNA1D (rank 3) encodes the α1D subunit of an L-type voltage-gated calcium channel expressed in adrenal chromaffin cells and vascular smooth muscle. CACNA1D variants connect aldosterone dysregulation and calcium channel activity to MAP, targeting a pathway directly addressed by calcium channel blocker medications.
TBC1D12 (rank 4) encodes a GTPase-activating protein for Rab GTPases involved in endosomal receptor trafficking. TBC1D12 may influence blood pressure through regulation of receptor recycling — affecting how efficiently key vascular receptors for angiotensin and catecholamines return to the cell surface after activation.
APOA1 (rank 5) encodes apolipoprotein A-I, the primary protein component of HDL cholesterol. Beyond reverse cholesterol transport, APOA1-containing HDL particles directly activate endothelial nitric oxide synthase, promoting vasodilation. An APOA1 MAP signal in a BMI-adjusted analysis reflects the endothelial-protective dimension of HDL biology, independent of obesity-related lipid changes.
Additional associated genes include ANO1 (Anoctamin-1/TMEM16A, a calcium-activated chloride channel expressed in vascular smooth muscle that influences membrane potential and contractility), ADRB1 (beta-1 adrenergic receptor, the direct target of beta-blocker antihypertensives), CASZ1 (zinc-finger transcription factor essential for vascular morphogenesis), ATP2B1 (plasma membrane calcium ATPase), and AGER (receptor for advanced glycation end-products, relevant to vascular inflammation in metabolic contexts).
Research snapshot: 85 genes identified for BMI-adjusted MAP by Pozarickij et al. (2024). FGF5, CACNA1D, APOA1, and ANO1 are among the leading signals — reflecting direct constitutional vascular mechanisms. Research base: Moderate.
What the research says
Pozarickij et al. (2024) applied a BMI-adjusted framework to mean arterial pressure, isolating genetic contributions to MAP independent of body weight. This approach reveals the constitutional blood pressure architecture — the inherited setpoint persisting regardless of adiposity changes.
The Moderate designation reflects the single-study basis for this specific phenotype definition. While top-ranked genes (FGF5, CACNA1D, ADRB1) have strong replication in other blood pressure analyses, the BMI-adjusted MAP phenotype specifically requires larger independent validation studies.
APOA1's rank-5 position is biologically compelling. HDL's vascular protective effects include endothelial nitric oxide production, which mediates vasodilation. A germline MAP signal at APOA1 connects the lipid metabolism protective arm to inherited blood pressure setpoints through an endothelial mechanism.
How mean arterial pressure affects you
BMI-adjusted MAP signals reflect genetic contributions to blood pressure present regardless of weight. FGF5 and SWAP70 confirm smooth muscle vascular growth factor biology; CACNA1D links calcium channel regulation and adrenal aldosterone; APOA1 introduces an HDL-endothelial vasodilation mechanism; ANO1 adds calcium-activated chloride channel biology as a vascular tone regulator.
ANO1 in vascular smooth muscle: ANO1 (TMEM16A) is a calcium-activated chloride channel expressed in smooth muscle and vascular pacemaker cells. Chloride efflux depolarizes smooth muscle membranes, triggering contraction. ANO1 variants that shift channel gating may modulate baseline vascular tone independently of classical calcium and adrenergic pathways.
Working with your variant profile
Sodium restriction, aerobic exercise, and the DASH dietary pattern reduce MAP across genetic backgrounds. For individuals whose results highlight CACNA1D signals, calcium channel blocker medications target the same pathway. For those with APOA1 signals, supporting HDL function through exercise, healthy fats, and smoking avoidance is particularly relevant from a vascular endothelial angle.
Consult a licensed healthcare provider before making treatment decisions based on genetic information.
Related traits and genes
- Systolic blood pressure — shares FGF5, SWAP70, CACNA1D
- Diastolic blood pressure — shares FGF5, CACNA1D, ADRB1, CASZ1, ATP2B1
- HDL cholesterol — APOA1 is the primary HDL protein gene
- Primary aldosteronism — CACNA1D gain-of-function variants appear in this adrenal condition
- Mean arterial pressure (unadjusted) — shares FGF5, SWAP70; broader unadjusted set includes adiposity-mediated pathways
Frequently asked questions
What does BMI adjustment mean for MAP genetics? Statistically removing body mass index from the MAP analysis isolates genetic effects that operate through direct vascular mechanisms rather than through weight gain as an intermediary. Variants retained after adjustment affect blood pressure constitutionally, independent of adiposity-mediated pathways.
Why does APOA1 — an HDL gene — appear in MAP genetics? APOA1 encodes the major HDL protein, which carries reverse cholesterol transport function and directly activates endothelial nitric oxide synthase, promoting vasodilation. Genetic variation near APOA1 may shift the capacity for HDL-mediated endothelial vasodilation, influencing MAP through a nitric oxide pathway independent of lipid levels or body weight.
What is ANO1 and how does it relate to blood pressure? ANO1 (TMEM16A) is a calcium-activated chloride channel expressed in vascular smooth muscle and interstitial pacemaker cells. Chloride efflux through ANO1 depolarizes smooth muscle membranes, triggering calcium entry and contraction. Variants that alter ANO1 gating may shift baseline smooth muscle membrane potential and vascular tone.
Why does FGF5 appear in both BMI-adjusted and unadjusted MAP analysis? FGF5's vascular smooth muscle paracrine signaling effect operates independently of body weight. Its rank-1 retention after BMI adjustment confirms a direct constitutional vascular mechanism, not an adiposity-mediated pathway — consistent with FGF5's appearance as the top signal across virtually every blood pressure phenotype definition.
What is TBC1D12 and why does it appear in blood pressure genetics? TBC1D12 is a GTPase-activating protein for Rab GTPases involved in endosomal receptor trafficking. It may influence MAP through regulation of receptor recycling — affecting how efficiently key vascular receptors for angiotensin and catecholamines are returned to the cell surface after agonist-driven internalization.
How does the BMI-adjusted MAP gene set compare to unadjusted MAP? The unadjusted MAP analysis (463 genes across nine studies) captures both direct and adiposity-mediated genetic effects. The BMI-adjusted analysis (85 genes) retains only constitutional direct-vascular signals. The smaller gene count reflects how many blood pressure loci exert part of their effect through weight-related pathways.
References:
- Pozarickij A et al. (2024). PMID 39048560.